Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Temple study identifies molecular mechanisms that may assist gene in blocking lung cancer


Dr Antonio Giordano, director of the Sbarro Institute for Cancer Research and Molecular Medicine based at Temple University.
Photo Credit: Joseph V. Labolito

The molecular mechanisms that may assist the tumor suppressing gene Rb2/p130 in blocking the progression of lung cancer cells has been clearly identified for the first time according to a study by researchers at Temple University’s Sbarro Institute for Cancer Research and Molecular Medicine.

The results of their study, "pRb2/p130 target genes in non-small cell lung cancer cells identified by microarray analysis," appear in the Oct. 9 issue of Oncogene (

The study, led by Antonio Giordano, M.D., Ph.D., head of the Sbarro Institute at Temple, was a follow-up to previous experiments led by Giordano that demonstrated an inverse relationship between Rb2 expression and the aggressiveness of lung cancer. Giordano discovered the Rb2 gene while working at Temple’s Fels Cancer Institute in the early 1990s. In those earlier studies, correct copies of Rb2 were introduced into mice with lung tumors using a viral system developed by Pier Paolo Claudio, M.D., Ph.D., associate professor of biotechnology at the Sbarro Institute. When the Rb2 gene was over-expressed in the cancer cells, it caused the tumors in the mice to completely regress(

"In this study, we wanted to understand the molecular mechanisms behind Rb2/p130 tumor growth inhibition," says Giuseppe Russo, Ph.D., a post doctoral fellow at the Sbarro Institute and the study’s lead author. "We wanted to know what this gene does in lung cancer cells, what other genes it may target, and how it controls cell regulation.

"It’s like this molecular process of tumor regression is a movie and Rb2 is the lead actor," Giordano adds. "What we wanted to know is who the supporting cast is."

After introducing correct copies of Rb2 into H23 lung cancer cells via Claudio’s viral shuttle, the researchers used customized microarray analysis to examine the simultaneous expression of thousands of genes within the cancer cell. Microarray is a powerful new tool that allows researchers to study the molecular basis of interactions on a scale that had been impossible using conventional methods.

"Through the use of the microarray, we were able to see which genes were over-expressed or under-expressed because of the enhanced Rb2 gene expression," says Giordano. "This is the first time that we have been able to clearly identify the genes that were being regulated by the Rb2 expression in lung cancer cells."

Some of the nearly 70 regulated genes that were identified through this study were previously known to be involved in the progression of lung cancer, says Giordano, meaning that the researchers were able to confirm previously published data. "But many of the identified genes were not previously known to be involved in lung cancer or be regulated by Rb2," he adds. The Temple researchers believe that identifying these genes could play an important role in developing future gene therapies to diagnose and treat lung cancer.

"Any regulation in a gene that is found to be caused by Rb2 is important to us because we can then study why that gene is regulated and use that information to develop molecular therapeutic approaches to lung cancer," says Giordano. "The gene expression profiles provided by microarray analysis will someday help tailor specific gene therapies to individual patients." Lung cancer is the leading cause of cancer death worldwide and is usually diagnosed at an incurable stage, most likely due to the absence of effective therapies as well as standard diagnostic procedures of early tumoral stages when compared with other cancers types, such as colon, breast and prostate cancers.

The study was funded by the National Institutes of Health and the Sbarro Health Research Organization.

Preston M. Moretz | Temple University
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>